Last reviewed · How we verify
NCT04598984
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
trial testing serum adipokines in Rectal Cancer Stage III in 60 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Istanbul Training and Research Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 September 2020 |
| Primary completion | 30 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- serum adipokines
Conditions studied
- Rectal Cancer Stage III — all drugs for Rectal Cancer Stage III →
Sponsor
Istanbul Training and Research Hospital
Who can join
18 and older, any sex, with Rectal Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04598984
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer Stage III
Currently open trials in the same condition.
- NCT06802172 — Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial · NA · recruiting
- NCT06968221 — Bovine Reinforcement in Stomach, Colorectal and Lung Operation · Phase 3 · recruiting
- NCT06565052 — The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treat · NA · recruiting
- NCT06254521 — The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer · Phase 2 · recruiting
- NCT05148767 — UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer · Phase 4 · recruiting
Other Istanbul Training and Research Hospital trials
Trials by the same sponsor.
- NCT07499713 — Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata · enrolling by invitation
- NCT07335822 — The Effectiveness of Low-Level Laser Therapy in the Treatment of Meralgia Paresthetica · NA · recruiting
- NCT07363187 — Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation · not yet recruiting
- NCT07415291 — CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis · active not recruiting
- NCT07150702 — Effects of Close Follow-up on Patients With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04598984 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Training and Research Hospital
- Last refreshed: 8 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598984.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing